The DOI matches its Crossref record.
Interaction of C-Reactive Protein Complexes with the Complement System
Abstract
The reaction of C-reactive protein (CRP)-positive sera and crystalline CRP with pneumococcal C-polysaccharide at equivalence induced consumption of human complement and C3 conversion in the absence of detectable antibody. Sera with negative or trace reaction for CRP most often gave no or minimal consumption of complement on addition of C-polysaccharide. Analysis of complement components consumed in the reaction of CRP-positive sera with C-polysaccharide, in the absence of detectable antibody, demonstrated consumption of 80% or more of total hemolytic complement, C1, C4, and C2, and 42 to 66% consumption of C3-9. Quantitative estimates of the minimal amount of CRP in acute phase sera which permitted fixation of complement closely approximated the minimal value obtained with crystalline CRP. All normal human sera tested permitted consumption of complement by CRP complexes, including sera from infants 5 to 7 months of age with physiologic hypogammaglobulinemia and sera previously absorbed with pneumococcal cell walls to remove any presumptive trace of antibody to C-polysaccharide. Both the CRP-C-polysaccharide precipitation and complement consumption reactions were 100% inhibited by phosphoryl choline but were not at all inhibited by N-acetyl galactosamine, the major determinant of antibody specificity. CRP reacted with phosphoryl choline of the choline phosphatides, lecithin and sphingomyelin, by complement fixation and by flocculation. Immunodiffusion analysis of the washed complexes obtained by reaction of CRP-positive sera with C-polysaccharide and with lecithin demonstrated strong lines of precipitation for CRP, C1q, and C3, whereas immunoglobulins were absent or detectable only in faint traces. These combined data have permitted the conclusion that complement consumption was attributable to CRP complexes and that it proceeded via the classical pathway independent of the presence of specific antibody or immunoglobulin. The specificity of CRP for choline phosphatides and its capacity to activate the complement system are considered in relation to the possible functions of CRP in the inflammatory process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Role of C-Reactive Protein at Sites of Inflammation and Infection
Sproston, N. R., & Ashworth, J. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00754 · Cited by 3,029
Pepys, M. B., & Baltz, M. L. (1983) · Advances in Immunology · doi:10.1016/s0065-2776(08)60379-x · Cited by 1,272
The physiological structure of human C-reactive protein and its complex with phosphocholine
Thompson, D., Pepys, M. B., & Wood, S. P. (1999) · Structure · doi:10.1016/s0969-2126(99)80023-9 · Cited by 818
“The capacity of human CRP to activate complement [16–20] and to stimulate tissue-factor production [21–23] suggests that CRP may have pro-inflammatory and procoagulant effects, and we have proposed [9,13] that these may contribute to pathogenesis of the progression and thrombo-occlusive complications of atheroma.”
BackgroundFunction of C-reactive protein
Du Clos, T. W. (2000) · Annals of Medicine · doi:10.3109/07853890009011772 · Cited by 801
Bruins, P., Velthuis, H. T., Yazdanbakhsh, A. P., Jansen, P. G. M., van Hardevelt, F. W. J., de Beaumont, E. M. F. H., Wildevuur, C. R. H., Eijsman, L., Trouwborst, A., & Hack, C. E. (1997) · Circulation · doi:10.1161/01.cir.96.10.3542 · Cited by 793
Gershov, D., Kim, S., Brot, N., & Elkon, K. B. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.9.1353 · Cited by 695
C-REACTIVE PROTEIN FIFTY YEARS ON
Pepys, M. B. (1981) · The Lancet · doi:10.1016/s0140-6736(81)91565-8 · Cited by 681
C-reactive protein: Ligands, receptors and role in inflammation
Marnell, L., Mold, C., & Du Clos, T. W. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.08.004 · Cited by 627
Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer
Allin, K. H., & Nordestgaard, B. G. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.599831 · Cited by 553
Is atrial fibrillation an inflammatory disorder?
Boos, C. J., Anderson, R. A., & Lip, G. Y. H. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi645 · Cited by 552
The Classical Complement Pathway: Activation and Regulation of the First Complement Component
Cooper, N. R. (1985) · Advances in Immunology · doi:10.1016/s0065-2776(08)60340-5 · Cited by 510
Griselli, M., Herbert, J., Hutchinson, W. L., Taylor, K. M., Sohail, M., Krausz, T., & Pepys, M. B. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.12.1733 · Cited by 508
Immunoglobulins and complement factors in senile plaques: An immunoperoxidase study
Eikelenboom, P., & Stam, F. C. (1982) · Acta Neuropathologica · doi:10.1007/bf00685397 · Cited by 454
Semple, S. C., Chonn, A., & Cullis, P. R. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00128-2 · Cited by 402
The Major Receptor for C-Reactive Protein on Leukocytes Is Fcγ Receptor II
Bharadwaj, D., Stein, M.-P., Volzer, M., Mold, C., & Clos, T. W. D. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.4.585 · Cited by 391
C-Reactive Protein Colocalizes With Complement in Human Hearts During Acute Myocardial Infarction
Lagrand, W. K., Niessen, H. W. M., Wolbink, G.-J., Jaspars, L. H., Visser, C. A., Verheugt, F. W. A., Meijer, C. J. L. M., & Hack, C. E. (1997) · Circulation · doi:10.1161/01.cir.95.1.97 · Cited by 388
Three dimensional structure of human C-reactive protein
Shrive, A. K., Gheetham, G. M. T., Holden, D., Myles, D. A. A., Turnell, W. G., Volanakis, J. E., Pepys, M. B., Bloomer, A. C., & Greenhough, T. J. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0496-346 · Cited by 356
Self-citationEngstad, R. E., Robertsen, B., & Frivold, E. (1992) · Fish & Shellfish Immunology · doi:10.1016/s1050-4648(06)80033-1 · Cited by 331
Regulation of complement activation by C-reactive protein
Mold, C., Gewurz, H., & Du Clos, T. W. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00007-7 · Cited by 326
Weiser, J. N., Pan, N., McGowan, K. L., Musher, D., Martin, A., & Richards, J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.631 · Cited by 304
Structural recognition and functional activation of FcγR by innate pentraxins
Lu, J., Marnell, L. L., Marjon, K. D., Mold, C., Du Clos, T. W., & Sun, P. D. (2008) · Nature · doi:10.1038/nature07468 · Cited by 301
Schultz, D. R., & Arnold, P. I. (1990) · Seminars in Arthritis and Rheumatism · doi:10.1016/0049-0172(90)90055-k · Cited by 293
DERNELLIS, J. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.04.025 · Cited by 290
Di Napoli, M., Schwaninger, M., Cappelli, R., Ceccarelli, E., Di Gianfilippo, G., Donati, C., Emsley, H. C. A., Forconi, S., Hopkins, S. J., Masotti, L., et al. (2005) · Stroke · doi:10.1161/01.str.0000165929.78756.ed · Cited by 289
De Córdoba, S. R., & De Jorge, E. G. (2007) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2007.03552.x · Cited by 287
Bovine and canine acute phase proteins
Eckersall, P. D., & Conner, J. G. (1988) · Veterinary Research Communications · doi:10.1007/bf00362798 · Cited by 273
Biology of C-Reactive Protein and the Acute Phase Response
Gewurz, H. (1982) · Hospital Practice · doi:10.1080/21548331.1982.11702332 · Cited by 80
Almeida, O. P., Norman, P. E., Allcock, R., Bockxmeer, F. V., Hankey, G. J., Jamrozik, K., & Flicker, L. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyp199 · Cited by 80
The Pentraxins 1975–2018: Serendipity, Diagnostics and Drugs
Pepys, M. B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02382 · Cited by 67
Perivascular deposits of serum proteins in cerebral cortex in vascular dementia
Alafuzoff, I., Adolfsson, R., Grundke-Iqbal, I., & Winblad, B. (1985) · Acta Neuropathologica · doi:10.1007/bf00690961 · Cited by 46
Metadata
- Authors
- Kaplan, M. H., & Volanakis, J. E.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1974-06-01
- Volume
- 112
- Issue
- 6
- Pages
- 2135-2147
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W4313309042
- Cited by
- 405
- References
- 0
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.